Intervisit variability of visual parameters in Leber congenital amaurosis caused by RPE65 mutations

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 2, 2013, Pages 1378-1383

  Roman, Alejandro J ^a   Cideciyan, Artur V ^a   Schwartz, Sharon B ^a   Olivares, Melani B ^a   Heon, Elise ^b   Jacobson, Samuel G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DATA ANALYSIS; FEMALE; GENE; GENE MUTATION; HUMAN; LEBER CONGENITAL AMAUROSIS; MALE; PERIMETRY; PRIORITY JOURNAL; RPE65 GENE; SCHOOL CHILD; VISUAL ACUITY; VISUAL FIELD; VISUAL SYSTEM PARAMETERS;

ADOLESCENT; ADULT; CHILD; CIS-TRANS-ISOMERASES; DNA; DNA MUTATIONAL ANALYSIS; ELECTRORETINOGRAPHY; FEMALE; HUMANS; LEBER CONGENITAL AMAUROSIS; MALE; MUTATION; PHENOTYPE; RETINA; RETROSPECTIVE STUDIES; VISUAL ACUITY; VISUAL FIELDS; YOUNG ADULT;

EID: 84874957891     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11341     Document Type: Article

References (45)

1. Jacobson SG, Cideciyan AV. Treatment possibilities for retinitis pigmentosa. N Engl J Med. 2010;363:1669-1671.
2. Cideciyan AV. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res. 2010;29:398-427.
3. Fishman GA, Jacobson SG, Alexander KR, et al. Outcome measures and their application in clinical trials for retinal degenerative diseases: outline, review, and perspective. Retina. 2005;25:772-777.
4. Bramall AN, Wright AF, Jacobson SG, McInnes RR. The genomic, biochemical, and cellular responses of the retina in inherited photoreceptor degenerations and prospects for the treatment of these disorders. Annu Rev Neurosci. 2010;33: 441-472.
5. Wright AF, Chakarova CF, Abd El-Aziz MM, Bhattacharya SS. Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait. Nat Rev Genet. 2010;11:273-284.
6. Ross DF, Fishman GA, Gilbert LD, Anderson RJ. Variability of visual field measurements in normal subjects and patients with retinitis pigmentosa. Arch Ophthalmol. 1984;102:1004-1010.
7. Berson EL, Sandberg MA, Rosner B, Birch DG, Hanson AH. Natural course of retinitis pigmentosa over a three-year interval. Am J Ophthalmol. 1985;99:240-251.
8. Birch DG, Anderson JL, Fish GE. Yearly rates of rod and cone functional loss in retinitis pigmentosa and cone-rod dystrophy. Ophthalmology. 1999;106:258-268.
9. Bittner AK, Iftikhar MH, Dagnelie G. Test-retest, within-visit variability of Goldmann visual fields in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2011;52:8042-8046.
10. Jacobson SG, Aleman TS, Cideciyan AV, et al. Identifying photoreceptors in blind eyes caused by RPE65 mutations: prerequisite for human gene therapy success. Proc Natl Acad Sci U S A. 2005;102:6177-6182.
11. Jacobson SG, Aleman TS, Cideciyan AV, et al. Human cone photoreceptor dependence on RPE65 isomerase. Proc Natl Acad Sci U S A. 2007;104:15123-15128.
12. Jacobson SG, Cideciyan AV, Aleman TS, et al. Photoreceptor layer topography in children with leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci. 2008; 49:4573-4577.
13. Jacobson SG, Aleman TS, Cideciyan AV, et al. Defining the residual vision in leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci. 2009;50:2368-2375.
14. Jacobson SG, Yagasaki K, Feuer WJ, Román AJ. Interocular asymmetry of visual function in heterozygotes of X-linked retinitis pigmentosa. Exp Eye Res. 1989;48:679-691.
15. Weleber RG, Tobler WR. Computerized quantitative analysis of kinetic visual fields. Am J Ophthalmol. 1986;101:461-468.
16. Dagnelie G. Conversion of planimetric visual field data into solid angles and retinal areas. Clin Vision Sci. 1990;5:95-100.
17. Schwartz SB, Aleman TS, Cideciyan AV, et al. Disease expression in Usher syndrome caused by VLGR1 gene mutation (USH2C) and comparison with USH2A phenotype. Invest Ophthalmol Vis Sci. 2005;46:734-743.
18. Herrera W, Aleman TS, Cideciyan AV, et al. Retinal disease in Usher syndrome III caused by mutations in the clarin-1 gene. Invest Ophthalmol Vis Sci. 2008;49:2651-2660.
19. Stone EM, Luo X, Heon E, et al. Autosomal recessive retinitis pigmentosa caused by mutations in the MAK gene. Invest Ophthalmol Vis Sci. 2011;52:9665-9673.
20. Jacobson SG, Cideciyan AV, Aleman TS, et al. Human retinal disease from AIPL1 gene mutations: foveal cone loss with minimal macular photoreceptors and rod function remaining. Invest Ophthalmol Vis Sci. 2011;52:70-79.
21. Jacobson SG, Cideciyan AV, Gibbs D, et al. Retinal disease course in Usher syndrome 1B due to MYO7A mutations. Invest Ophthalmol Vis Sci. 2011;52:7924-7936.
22. Huang WC, Wright AF, Roman AJ, et al. RPGR-associated retinal degeneration in human X-linked RP and a murine model. Invest Ophthalmol Vis Sci. 2012;53:5594-5608.
23. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Report number 1. Arch Ophthalmol. 1985;103:1796-1806.
24. Bressler NM, Bressler SB, Hawkins BS, et al. Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. Ophthalmic outcomes submacular surgery trials pilot study report number 1. Am J Ophthalmol. 2000;130:387-407.
25. Bland JM, Altman DG. Measurement error. BMJ. 1996;313:744.
26. Nevill AM, Atkinson G. Assessing agreement between measurements recorded on a ratio scale in sports medicine and sports science. Br J Sports Med. 1997;31:314-318.
27. Jacobson SG, Cideciyan AV, Peshenko IV, et al. Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants. Hum Mol Genet. 2013; 22:168-183.
28. Rosser DA, Cousens SN, Murdoch IE, Fitzke FW, Laidlaw DAH. How sensitive to clinical change are ETDRS logMAR visual acuity measurements? Invest Ophthalmol Vis Sci. 2003;44: 3278-3281.
29. Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993;111:761-772.
30. Berson EL, Rosner B, Sandberg MA, et al. Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol. 2010;128:403-411.
31. Fishman GA, Bozbeyoglu S, Massof RW, Kimberling W. Natural course of visual field loss in patients with Type 2 Usher syndrome. Retina. 2007;27:601-608.
32. Aleman TS, Jacobson SG, Chico JD, et al. Impairment of the transient pupillary light reflex in Rpe65(-/-) mice and humans with leber congenital amaurosis. Invest Ophthalmol Vis Sci. 2004;45:1259-1271.
33. Roman AJ, Schwartz SB, Aleman TS, et al. Quantifying rod photoreceptor-mediated vision in retinal degenerations: darkadapted thresholds as outcome measures. Exp Eye Res. 2005; 80:259-272.
34. Roman AJ, Cideciyan AV, Aleman TS, Jacobson SG. Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials. Physiol Meas. 2007;28: N51-N56.
35. Brown B, Lovie-Kitchin J. Repeated visual acuity measurement: establishing the patient's own criterion for change. Optom Vis Sci. 1993;70:45-53.
36. Bittner AK, Ibrahim MA, Haythornthwaite JA, Diener-West M, Dagnelie G. Vision test variability in retinitis pigmentosa and psychosocial factors. Optom Vis Sci. 2011;88:1496-1506.
37. Massof R, Dagnelie G, Benzschawel T, Palmer R, Finkelstein D. First order dynamics of visual field loss in retinitis pigmentosa. Clin Vision Sci. 1990;5:1-26.
38. Ferris FL III, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94: 91-96.
39. Bailey IL, Bullimore MA, Raasch TW, Taylor HR. Clinical grading and the effects of scaling. Invest Ophthalmol Vis Sci. 1991;32:422-432.
40. Vanden Bosch ME, Wall M. Visual acuity scored by the letter-by-letter or probit methods has lower retest variability than the line assignment method. Eye (Lond). 1997;11:411-417.
41. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009;374:1597-1605.
42. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012;4:120ra15.
43. Gao S-Q, Maeda T, Okano K, Palczewski K. A microparticle/ hydrogel combination drug-delivery system for sustained release of retinoids. Invest Ophthalmol Vis Sci. 2012;53: 6314-6323.
44. Kaylor JJ, Yuan Q, Cook J, et al. Identification of DES1 as a vitamin A isomerase in M̈uller glial cells of the retina. Nat Chem Biol. 2013;9:30-36.
45. Cideciyan AV, Rachel RA, Aleman TS, et al. Cone photoreceptors are the main targets for gene therapy of NPHP5 (IQCB1) or NPHP6 (CEP290) blindness: generation of an all-cone Nphp6 hypomorph mouse that mimics the human retinal ciliopathy. Hum Mol Genet. 2011;20:1411-1423.